41 completed, 11 unknown, 5 recruiting, 5 withdrawn. 71 Phase 2, 15 Phase 3, 10 Phase 1.
Follow Vaginitis: new trials by email Literature Review of Vaginitis trials Research Report on Vaginitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole, Placebo Vaginal Capsule Metronidazole - Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | SPH Sine Pharmaceutical Laboratories Co., Ltd. | 150 | 2026-10-20 | 2026-10-22 |
| MOTIF@FRESH: Modifying Organisms Transvaginally in Females @ FRESH Vaginal Microbiome Transplantation (VMT), oral metronidazole, Sterile saline solution - Recurrent Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | Douglas Kwon | 75 | 2026-09-01 | 2026-05-18 |
| Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence OCF001 Intravaginal Gel, Placebo Gel - Candidiasis, Vulvovaginal | Phase 2 | Recruiting | Sano Chemicals Inc | 36 | 2026-06-04 | 2026-06-15 |
| Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients BPR-101 capsules:Investigational product for the treatment of BV, Placebo：matching the investigational product in appearance, dosage form, and route of administration - Bacterial Vaginosis | Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 80 | 2026-04-15 | 2026-03-19 |
| Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis | Phase 2 / Phase 3 | Not yet recruiting | Kaneka Americas Holding Inc. | 160 | 2026-04-01 | 2026-04-14 |
| Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial FB 301, Chlorhexidine 0.5%, metronidazole 500 mg - Bacterial Vaginosis (BV) | Phase 2 | Recruiting | Freya Biosciences ApS | 120 | 2026-03-23 | 2026-08-06 |
| A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients WXSH0102/placebo, fluconazole capsules/placebo - Vaginitis | Phase 2 | Recruiting | Cisen Pharmaceutical CO., LTD. | 108 | 2025-01-13 | 2025-02-13 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose - Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Recruiting | AVVA Pharmaceuticals Ltd. | 264 | 2024-02-29 | 2025-02-19 |
| Vaginal Hyaluronic Acid, Arginine and Liposome Gel Versus Vaginal Lubricant in Postmenopausal Women With Genitourinary Syndrome of Menopause Vaginal Gel, Vaginal lubricant - Menopause Related Conditions, Atrophic Vaginitis | Phase 2 / Phase 3 | Unknown | Sarawak General Hospital | 52 | 2024-01-01 | 2023-12-28 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs Menstrual Cup - Bacterial Vaginosis, Vaginal Microbiome | Phase 2 | Completed | Rush University Medical Center | 408 | 2023-02-13 | 2026-08-24 |
| Live Double Combined Lactobacillus Capsule for Vaginal Use(IIb) Vaginal Lactobacillus Dual Probiotic Capsules, Placebo - Bacterial Vaginosis | Phase 2 | Completed | Guangdong Longchuangji Pharmaceutical Co., Ltd. | 66 | 2023-01-03 | 2026-02-18 |
| Role of Oral Lactoferrin in Prevention of Recurnt Bacterial Vaginosis in Pregnancy lactoferrin - Bacterial Vaginosis | Vaginal | Microbiology | Phase 2 / Phase 3 | Unknown | Zagazig University | 66 | 2022-07-01 | 2023-01-03 |
| Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis. Venus 20 + 0,064, Venus 20 + 1, Venus 20 + 4 - Vulvovaginal Candidiasis | Phase 2 | Withdrawn | EMS | 2022-07-01 | 2022-08-10 | |
| A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis Chlorhexidine Gluconate, Fluconazole - Candidiasis, Vulvovaginal | Phase 2 | Unknown | Karolinska Institutet | 60 | 2022-04-27 | 2022-05-20 |
| Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study Secnidazole 2 GM Oral Granules - Recurrent Bacterial Vaginosis | Phase 2 / Phase 3 | Completed | Indiana University | 24 | 2021-07-09 | 2024-02-05 |
| Live Double Combined Lactobacillus Capsule for Vaginal Use（IIa） Live double combined lactobacillus capsule for vaginal use（1*10^7CFU/capsule）+Metronidazole placebo, Low-dose group: Live double combined lactobacillus capsule placebo+Metronidazole, Live double combined lactobacillus capsule for vaginal use（1*10^8CFU/capsule）+Metronidazole placebo - Bacterial Vaginosis (BV) | Phase 2 | Completed | Guangdong Longchuangji Pharmaceutical Co., Ltd. | 57 | 2021-05-18 | 2026-02-18 |
| Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition LACTIN-V, Placebo - Bacterial Vaginosis, HIV Infections | Phase 2 | Completed | University of California, San Francisco | 45 | 2021-05-10 | 2024-08-13 |
Showing 20 of 71. Sign in to see all of them.
Vaginosis, Bacterial (38) · Candidiasis, Vulvovaginal (23) · Atrophic Vaginitis (4) · HIV Infections (4) · Trichomonas Vaginitis (4) · Vaginal Diseases (4) · Candidiasis (3) · Sexually Transmitted Diseases (3) · Vulvovaginitis (3) · Recurrence (2) · Syphilis (2) · Trichomonas Infections (2) · Acquired Immunodeficiency Syndrome (1) · Atypical Squamous Cells of the Cervix (1)
Female Urogenital Diseases (71) · Female Urogenital Diseases and Pregnancy Complications (71) · Genital Diseases (71) · Genital Diseases, Female (71) · Urogenital Diseases (71) · Vaginal Diseases (67) · Bacterial Infections and Mycoses (60) · Infections (60) · Bacterial Infections (40) · Vulvar Diseases (23) · Vulvitis (23) · Mycoses (22) · Candidiasis (20) · Vulvovaginitis (20)
Metronidazole (12) · Fluconazole (8) · Clotrimazole (3) · Benchmarking (2) · TOL-463 (2) · VT-1161 (2) · Vaginal Creams, Foams, and Jellies (2) · ibrexafungerp (2) · Amoxicillin (1) · Clindamycin (1) · Dosage Forms (1) · Drug Administration Routes (1) · Estradiol (1) · Glucose (1) · Imiquimod (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Douglas Kwon (2) · Guangdong Longchuangji Pharmaceutical Co., Ltd. (2) · Karolinska Institutet (2) · Matinas BioPharma Nanotechnologies, Inc. (2) · Population Council (2) · ProFem GmbH (2) · Scynexis, Inc. (2) · Starpharma Pty Ltd (2) · Viamet (2) · AVVA Pharmaceuticals Ltd. (1) · Alfasigma S.p.A. (1) · Assiut University (1) · Avva Rus, JSC (1) · CDA Research Group, Inc. (1)
United States (33) · China (5) · Canada (3) · South Africa (3) · Austria (2) · Israel (2) · Kenya (2) · Poland (2) · Russia (2) · Sweden (2) · Tanzania (2) · Belarus (1) · Belgium (1) · Brazil (1) · Denmark (1)
David Angulo, MD (2) · Ahinoam Lev-Sagie (1) · Alena Jandourek, MD (1) · Amal Mohamed Alanwar, MD (1) · Andrea R Thurman, MD (1) · Anke Hemmerling, MD, MPH, PhD (1) · Anne Macek, MD (1) · Ashwin Chatwani, MD (1) · Caroline Mitchell, MD, MPH (1) · Cathrin Alvendal, MD, PhD (1) · Charlotte E. Ellertson, MPA, Ph.D. (1) · Chemen Neal, MD (1) · Christina Muzny, MD (1) · Craig R Cohen, MD MPH (1) · Craig R Cohen, MD, MPH (1)
PMID 36396498, PMID 20644497, PMID 20801446, PMID 21992977, PMID 24983350, PMID 25935783, PMID 26210791, PMID 28697102, PMID 29304768, PMID 29474292, PMID 29534874, PMID 29697768, PMID 30184181, PMID 30807423, PMID 32402161, PMID 32818963, PMID 33207004, PMID 34555149, PMID 35113809, PMID 37619252, PMID 39516733, PMID 40194532, PMID 40206350, PMID 40970688, PMID 41845293, PMID 42326018, PMID 42678149
2009 (1), 2023 (1), 2025 (1), R01AI045468 (1), R01AI170564 (1), R01HD098978 (1)